Loading...
XASXFPH
Market cap12bUSD
Dec 20, Last price  
34.18AUD
1D
0.89%
1Q
1.39%
Jan 2017
317.34%
Name

Fisher & Paykel Healthcare Corporation Ltd

Chart & Performance

D1W1MN
XASX:FPH chart
P/E
167.03
P/S
12.60
EPS
0.23
Div Yield, %
0.73%
Shrs. gr., 5y
0.28%
Rev. gr., 5y
11.30%
Revenues
1.74b
+17.21%
241,136,000289,547,000349,242,000345,966,000485,516,000474,755,000467,680,000466,726,000507,250,000568,602,000644,013,000738,745,431796,785,293907,090,1961,029,311,9291,233,448,8931,791,400,9131,521,301,5841,486,891,5781,742,800,000
Net income
133m
-47.02%
61,405,00069,965,00057,605,00035,276,00062,233,00071,631,00052,466,00064,110,00077,053,00097,053,000113,173,000143,425,000169,152,000190,200,000209,200,000287,300,000524,200,000376,900,000250,300,000132,600,000
CFO
430m
+92.69%
66,380,45282,443,58956,346,00038,375,87651,318,835106,508,33052,244,85273,981,87569,349,32697,644,686144,023,540130,487,997177,379,035233,050,234243,190,664311,316,533574,973,304300,388,519222,949,498429,600,000
Dividend
Jun 26, 20240.21374 AUD/sh
Earnings
May 27, 2025

Profile

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It also provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers Airvo 2, a humidified nasal high flow system; Optiflow, a nasal high flow therapy; and F&P 850 System, a noninvasive and invasive ventilation system. In addition, it provides infant respiratory products, such as resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products, including humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, humidifiers, and accessories. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
URL
https://www.fphcare.com/
IPO date
Nov 13, 2001
Employees
6,391
Domiciled in
NZ
Incorporated in
NZ

Valuation

Title
NZD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
1,742,800
17.21%
1,486,892
-2.26%
1,521,302
-15.08%
Cost of revenue
1,389,400
1,168,941
1,089,383
Unusual Expense (Income)
NOPBT
353,400
317,951
431,918
NOPBT Margin
20.28%
21.38%
28.39%
Operating Taxes
103,100
72,725
117,914
Tax Rate
29.17%
22.87%
27.30%
NOPAT
250,300
245,226
314,005
Net income
132,600
-47.02%
250,300
-33.59%
376,900
-28.10%
Dividends
(145,500)
(195,700)
(224,900)
Dividend yield
1.05%
1.35%
1.73%
Proceeds from repurchase of equity
3,000
3,000
3,996
BB yield
-0.02%
-0.02%
-0.03%
Debt
Debt current
96,200
21,300
15,747
Long-term debt
167,800
166,993
80,863
Deferred revenue
42,493
Other long-term liabilities
44,700
26,473
55,947
Net debt
182,000
(18,464)
(256,113)
Cash flow
Cash from operating activities
429,600
222,949
300,389
CAPEX
(316,800)
(197,772)
(157,280)
Cash from investing activities
(339,000)
(10,577)
(82,901)
Cash from financing activities
(128,700)
(184,481)
(218,414)
FCF
11,668
(14,901)
79,880
Balance
Cash
82,000
113,253
268,525
Long term investments
93,504
84,198
Excess cash
132,413
276,658
Stockholders' equity
1,759,100
1,644,229
1,560,575
Invested Capital
1,992,900
1,653,368
1,379,694
ROIC
13.73%
16.17%
25.94%
ROCE
17.73%
17.78%
26.08%
EV
Common stock shares outstanding
586,179
581,631
579,993
Price
23.66
-4.83%
24.86
10.73%
22.45
-23.61%
Market cap
13,868,994
-4.08%
14,459,345
11.05%
13,020,834
-23.49%
EV
14,050,994
14,440,881
12,764,721
EBITDA
462,500
410,613
520,840
EV/EBITDA
30.38
35.17
24.51
Interest
18,200
6,271
4,539
Interest/NOPBT
5.15%
1.97%
1.05%